Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1014

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 1014
---
 “February 2025 Placement Agent Warrants”) to purchase up to 22,554
shares of common stock. The February 2025 Placement Agent Warrants have an exercise price equal to $4.469 per share and are exercisable
upon issuance, or February 6, 2025, and expire twenty-four months from the date of issuance, or February 8, 2027. 

The February 2025 Offering closed on February
6, 2025, resulting in net proceeds to the Company of approximately $908,627, after deducting the placement agent fees and other offering
expenses paid by the Company.

1:5 Reverse Stock Split

On February 18, 2025, the Company filed an amendment
to its Certificate of Incorporation with the Secretary of State of Delaware to effect the 1:5 Reverse Stock Split, which was effective
as of February 24, 2025. The Company’s stockholders approved a reverse stock split at a ratio ranging from 1:3 to 1:5 at the 2024
Special Stockholders Meeting on November 6, 2024, and subsequently on February 10, 2025, the Company’s Board of Directors approved
the implementation of the reverse stock split at a ratio of 1:5.

As of the effective time of the 1:5 Reverse Stock
Split, every five (5) issued and outstanding shares of the Company’s common stock were automatically combined and converted into
one (1) issued and outstanding share of the Company’s common stock, reducing the number of shares of common stock outstanding from
7,364,554 shares to 1,472,891 shares. The 1:5 Reverse Stock Split did not change the authorized number of shares of common stock or preferred
stock. Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company’s
equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable
in accordance with the terms of the instruments. No fractional shares of common stock were issued in connection with the 1:5 Reverse
Stock Split. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock.

Unless otherwise noted, all references to numbers
of shares of the Company’s common stock and per share information presented in these consolidated financial statements have been
retroactively adjusted, as appropriate, to